» Articles » PMID: 35115860

The Impact of Stigma on People with Opioid Use Disorder, Opioid Treatment, and Policy

Overview
Publisher Dove Medical Press
Specialty Psychiatry
Date 2022 Feb 4
PMID 35115860
Authors
Affiliations
Soon will be listed here.
Abstract

Illicit drug use disorders are the most stigmatised health conditions worldwide, and stigma acts as a meaningful barrier to treatment entry and treatment provision. In the context of dramatically rising opioid-related harms, it is critical that we understand the drivers of stigma and how it affects opioid use disorder treatment and policy. The aim of this narrative review is to discuss how opioid-related stigma impacts treatment provision and harm reduction, and provide potential strategies to reduce stigma at a social and structural level. We used the Framework for Integrating Normative Influences on Stigma (FINIS) to identify sources of opioid-related stigma at the macro (structural stigma), meso (public stigma) and micro (internalised stigma) levels. Reducing stigma requires strategies that target multiple levels, however addressing inequity in the laws, regulations, and rules that segregate people with opioid and other substance use disorders from mainstream society is essential.

Citing Articles

The effectiveness of a transtheoretical model based on health education intervention on adherence to methadone maintenance treatment: a quasi-experimental study.

Khalan Y, Kaveh M, Karimi M, Zare E, Asadollahi A BMC Public Health. 2025; 25(1):856.

PMID: 40038646 PMC: 11877681. DOI: 10.1186/s12889-025-22067-x.


Care for patients with cancer and substance use disorders: a qualitative study of oncology team experiences.

Kale S, Rush L, Eramo J, Bitangacha M, Chen S, Check D Support Care Cancer. 2025; 33(2):146.

PMID: 39903305 PMC: 11794404. DOI: 10.1007/s00520-025-09181-7.


People who use drugs and the right to health.

Ritter A, Barrett L Harm Reduct J. 2024; 21(1):215.

PMID: 39617904 PMC: 11610087. DOI: 10.1186/s12954-024-01132-5.


"Just Google It": A Qualitative Study of Reproductive-Age Women's Stigmatizing Experiences When Accessing Buprenorphine for Opioid Use Disorder.

Bulgin D, McBride Murry V, McElroy T, Schlundt D, Bonnet K, Patrick S Womens Health Issues. 2024; 35(1):45-53.

PMID: 39603927 PMC: 11851233. DOI: 10.1016/j.whi.2024.10.003.


Reviewing the Impact of Maternal Opioid Use Disorder on Fetal Development and Long-Term Pediatric Health Outcomes.

Asad M, Bonner-Reid F, Aldoohan F, Marrelli L, Ghanie N, Attia Hussein Mahmoud H Cureus. 2024; 16(10):e72192.

PMID: 39583351 PMC: 11583522. DOI: 10.7759/cureus.72192.


References
1.
Del Pozo B, Sightes E, Kang S, Goulka J, Ray B, Beletsky L . Can touch this: training to correct police officer beliefs about overdose from incidental contact with fentanyl. Health Justice. 2021; 9(1):34. PMC: 8612110. DOI: 10.1186/s40352-021-00163-5. View

2.
Pescosolido B, Martin J, Lang A, Olafsdottir S . Rethinking theoretical approaches to stigma: a Framework Integrating Normative Influences on Stigma (FINIS). Soc Sci Med. 2008; 67(3):431-40. PMC: 2587424. DOI: 10.1016/j.socscimed.2008.03.018. View

3.
Haight B, Learned S, Laffont C, Fudala P, Zhao Y, Garofalo A . Efficacy and safety of a monthly buprenorphine depot injection for opioid use disorder: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2019; 393(10173):778-790. DOI: 10.1016/S0140-6736(18)32259-1. View

4.
Wild T, Koziel J, Anderson-Baron J, Asbridge M, Belle-Isle L, Dell C . Public support for harm reduction: A population survey of Canadian adults. PLoS One. 2021; 16(5):e0251860. PMC: 8133460. DOI: 10.1371/journal.pone.0251860. View

5.
McGinty E, Stone E, Kennedy-Hendricks A, Barry C . Stigmatizing language in news media coverage of the opioid epidemic: Implications for public health. Prev Med. 2019; 124:110-114. DOI: 10.1016/j.ypmed.2019.03.018. View